About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
A
Surveying BTKi Options for CLL Treatment: Ibrutinib / Zanubrutinib / Acalabrutinib / Pirtobrutinib Efficacy Data & Combination Therapy Considerations
By
Adam Kittai
2 Videos
191 views
May 3, 2021
0 Comments
Login to view comments.
Click here to Login
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Related Content
AUTOPLAY
ON
12:47
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Summary: "Experts Discuss Key Abstracts in CLL"
Feat.
S. O'Brien,
C. Coombs
17:05
Cleveland Clinic Taussig Cancer Institute
Frontline CLL Learnings From Phase 3 RESONATE-2, iLLUMINATE, and E19…
Feat.
A. Winter
08:17
Adam Kittai
Highlights From iwCLL 2023: What's New and Practice Informing i…
06:56
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Efficacy of Ibrutinib Arms Across ALPINE an…
Feat.
M. Shadman
15:21
5th SOHO Italy Annual Conference
SOHO Italy 2023: How I Treat CLL at the MD Anderson Cancer Center
Feat.
A. Ferrajoli
08:45
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "The Best of CLL - Highlights & Key Takea…
Feat.
V. Yazbeck
06:28
Insights from 2023 EHA® Annual Meeting
EHA® 2023 Insights: "Venetoclax + Obinutuzumab for Previously U…
Feat.
O. Al-Sawaf
06:21
City of Hope
Cardiac Safety of Zanubrutinib vs. Other BTKis in CLL
Feat.
A. Danilov
11:39
5th SOHO Italy Annual Conference
SOHO Italy 2023: Current Approach to Sequencing CLL Therapy in the R…
Feat.
G. Gaidano
18:01
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "MRD-Directed Therapy in CLL - Ready for Pri…
Feat.
J. Rhodes
05:12
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Fixed-Duration Pirtobrutinib Combined With …
Feat.
N. Shah
10:19
Alvaro Alencar
Pirtobrutinib in R/R CLL
10:22
SOHO 2023 Eleventh Annual Meeting
SOHO 2023 Next Questions: CLL
Feat.
N. Jain
28:43
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2023
Scripps MD Anderson Cancer Center Updates on CLL/SLL Frontline Thera…
Feat.
S. O'Brien
17:21
Daniel Addison
Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…
10:35
Alan Skarbnik
Learnings From the ELEVATE-TN Phase 3 Trial: Acalabrutinib+/-Obinutu…
08:26
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Pirtobrutinib in Post-cBTKi CLL/SLL - 30 Mo…
Feat.
J. Woyach
16:16
Insights from 2023 EHA® Annual Meeting
Experts Discuss Key Updates in CLL From EHA and iCML
Feat.
S. O'Brien,
C. Coombs
36:40
Penn Medicine Abramson Cancer Center
Penn Medicine Abramson Cancer Center Updates on Managing CLL/SLL Wit…
Feat.
J. Carter,
M. Hughes
14:05
The University of Kansas Cancer Center
Five-Year Updates on Venetoclax + Obinutuzumab for Previously Untrea…
Feat.
M. Hoffmann
